Home / Deep Research / Stargardt Disease

Stargardt Disease

Disease Pathophysiology Research Template

2026-02-27
Falcon MONDO:0019353 Model: Edison Scientific Literature 32 citations

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Stargardt Disease
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Stargardt Disease. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology of Stargardt Disease (STGD1; ABCA4-associated retinopathy) — 2023–2024 Evidence-focused Research Report

  1. Disease overview and key definitions

Stargardt disease type 1 (STGD1) is the most common inherited macular dystrophy / juvenile-onset macular degeneration, classically caused by biallelic pathogenic variants in ABCA4 (OMIM: 248200). Recent reviews summarize prevalence estimates around ~1:8,000–1:10,000 and emphasize wide phenotypic heterogeneity and uncertainty due to limited population-based studies. (gomezbenlloch2024opticalcoherencetomography pages 2-4, wang2023updatesonemerging pages 1-2, ng2024impairedcathepsind pages 1-3)

Core biochemical definition (ABCA4 retinopathy): ABCA4 encodes an ATP-binding cassette transporter (“flippase”) that participates in retinoid handling in photoreceptor outer-segment (OS) disc membranes by transporting the Schiff-base retinoid–phospholipid adduct N-retinylidene-phosphatidylethanolamine (N-ret-PE / NrPE) across the disc membrane; loss of ABCA4 function increases toxic bisretinoid formation and downstream retinal pigment epithelium (RPE) lipofuscin accumulation. (fujinami2024stargardtmaculardystrophy pages 2-2, wang2023updatesonemerging pages 2-4)

Figure-based summary: a recent concise review provides a schematic linking ABCA4’s role in the visual cycle to bisretinoid accumulation and retinal degeneration, and a table summarizing therapeutic approaches and development status. (fujinami2024stargardtmaculardystrophy media 07d7554f, fujinami2024stargardtmaculardystrophy media 5aab47f1)

  1. Core pathophysiology (molecular and cellular mechanisms)

2.1 Primary molecular trigger: defective ABCA4-mediated retinoid adduct clearance

Mechanistic sequence (current consensus, reiterated in 2023–2024 reviews):

• Photobleaching releases all-trans-retinal (atRAL), which forms a Schiff-base adduct with phosphatidylethanolamine (PE) to yield N-retinylidene-PE (N-ret-PE). ABCA4 normally transports N-ret-PE; when ABCA4 is dysfunctional or mislocalized, N-ret-PE is retained and bisretinoid precursors accumulate in OS membranes. (fujinami2024stargardtmaculardystrophy pages 2-2)

• A2PE (a bisretinoid phosphatidylethanolamine adduct) forms in photoreceptor OS and, after OS shedding and phagocytosis by RPE, is hydrolyzed in acidic phagolysosomes to the bisretinoid A2E, which accumulates as a major lipofuscin fluorophore within RPE lysosomes. (wang2023updatesonemerging pages 2-4, watson2023unravellingstargardtdisease pages 35-39, fujinami2024stargardtmaculardystrophy pages 2-2)

2.2 Downstream toxic mechanisms: bisretinoid/lipofuscin-driven RPE dysfunction and secondary photoreceptor degeneration

Oxidative/photooxidative stress: Reviews summarize that A2E and related bisretinoids within lipofuscin can generate reactive oxygen species (ROS) upon light exposure, increasing oxidative stress and promoting RPE apoptosis. (ghenciu2024emergingtherapeuticapproaches pages 4-5)

RPE phagocytosis and degradative failure: Accumulated toxic byproducts are described as disrupting RPE phagocytosis and degradation of photoreceptor outer segments, leading to secondary photoreceptor degeneration (notably macular cone loss and central vision loss). (ghenciu2024emergingtherapeuticapproaches pages 4-5)

RPE-autonomous pathology is increasingly emphasized (2024 primary study): a 2024 mechanistic paper reports that “Loss of functional ABCA4 in the retinal pigment epithelium (RPE) alone, without contribution from photoreceptor cells, was shown to induce STGD1 pathology” and identifies lysosomal Cathepsin D (CatD) impairment as a key contributor to STGD1 RPE endo-lysosomal dysfunction. (ng2024impairedcathepsind pages 1-3)

2.3 Endo-lysosomal dysfunction axis (2024): lysosomal alkalinization → Cathepsin D impairment → impaired outer-segment degradation

A key recent advance is mechanistic linkage of ABCA4 dysfunction to RPE lysosomal physiology:

• Patient-derived iPSC-RPE from STGD1 patients exhibited “elevated lysosomal pH” (lysosomal alkalinization), consistent with prior Abca4−/− mouse findings. (ng2024impairedcathepsind pages 1-3)

• CatD (the “primary RPE lysosomal protease”) requires acidic pH for maturation and activity; CatD maturation and activity were impaired in STGD1 patient RPE and Abca4−/− mice, resulting in reduced photoreceptor outer-segment degradation. (ng2024impairedcathepsind pages 1-3)

• The same study reports intracellular accumulation of autofluorescent material and PE in STGD1 RPE, and proposes altered PE distribution compromises LC3-associated phagocytosis, contributing to delayed endo-lysosomal degradation. (ng2024impairedcathepsind pages 1-3, ng2024impairedcathepsind pages 12-13)

• The authors also report that STGD1 patient-derived RPE display “significant accumulation of α-synuclein,” a CatD substrate; and they propose α-synuclein accumulation could exacerbate trafficking/lysosomal hydrolase delivery problems. (ng2024impairedcathepsind pages 12-13)

Therapeutic implication (mechanism-based): “Drug-mediated re-acidification of lysosomes … restores CatD functional activity,” supporting lysosomal pH/CatD as a targetable axis in ABCA4 retinopathy. (ng2024impairedcathepsind pages 1-3)

2.4 Inflammation/complement contributions and modifier pathways

Complement-related signals appear in multiple recent mechanistic and translational sources, though the strength and locus of activation can vary across models:

• A 2024 translational modifier-gene therapy paper in Abca4−/− mice links ABCA4-related vitamin A byproducts (including A2E) to complement dysregulation and reports that A2E can “interfere with CD59 recycling upon MAC activation, leading to its reduced expression in Abca4−/− mice,” positioning complement regulation as part of disease biology. (akula2024retinoicacidrelated pages 7-8)

• The same study frames RORα (RORA) as regulating an “AMD inflammation pathway that includes ABCA4, CD59, C3 and C5,” and reports AAV5-hRORA treatment reduced deposits and restored CD59 expression with functional improvement in Abca4−/− mice. (akula2024retinoicacidrelated pages 7-8)

• A separate mouse-study excerpt assessing complement factor D (CFD) reports that in their assay C3 immunofluorescence did not differ significantly across genotypes and concludes complement “was not wholly activated” in their samples, highlighting that complement readouts can be context-dependent and assay-limited. (xie2024assayingtherole pages 36-40)

  1. Key molecular players and affected cell types/anatomical locations

3.1 Genes/proteins (HGNC symbols) supported by recent evidence

Primary causal gene

• ABCA4 (HGNC:34; ATP-binding cassette subfamily A member 4): causal gene in autosomal recessive STGD1; localized to rod/cone outer-segment disc membranes; acts as a flippase transporting retinoid adducts (NrPE/N-ret-PE). (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 2-2)

Visual-cycle and retinoid-handling components (mentioned in mechanistic descriptions)

• RDH enzymes (retinol dehydrogenases): reduction of all-trans-retinal to all-trans-retinol is described as part of retinoid processing in the context of ABCA4 dysfunction, and Abca4−/−Rdh8−/− models are referenced as relevant to bisretinoid accumulation. (xie2024assayingtherole pages 5-11, yu2025mechanismsandfunctions pages 10-11)

Endo-lysosomal machinery

• CTSD (Cathepsin D): identified as “the primary RPE lysosomal protease” and impaired (maturation/activity) in STGD1 patient-derived iPSC-RPE and Abca4−/− mouse RPE, mediating delayed outer-segment degradation. (ng2024impairedcathepsind pages 1-3)

• SNCA (α-synuclein): reported to accumulate in STGD1 patient-derived RPE; discussed as relevant to vesicle trafficking and lysosomal dysfunction. (ng2024impairedcathepsind pages 12-13)

Inflammation/complement/regulators (evidence from translational and model studies)

• CD59, C3, C5: described as part of an inflammation/complement pathway regulated by RORA in an Abca4−/− context; CD59 restoration and reduced deposits are reported with AAV5-hRORA therapy in Abca4−/− mice. (akula2024retinoicacidrelated pages 7-8)

• RORA: modifier/therapeutic target proposed to regulate inflammatory/complement and other pathways; AAV5-hRORA treatment reported to improve molecular and functional readouts in Abca4−/− mice. (akula2024retinoicacidrelated pages 7-8)

3.2 Chemical entities / metabolites (CHEBI names where applicable)

• all-trans-retinal: photobleaching product; forms N-ret-PE and participates in bisretinoid precursor formation. (fujinami2024stargardtmaculardystrophy pages 2-2)

• phosphatidylethanolamine (PE): forms Schiff-base adduct with retinal (N-ret-PE) and is implicated in membrane fusion and endo-lysosome maturation; PE aggregation/redistribution is reported in STGD1 patient RPE and proposed to impair vesicle–endo-lysosome fusion and lysosomal acidification. (ng2024impairedcathepsind pages 12-13, fujinami2024stargardtmaculardystrophy pages 2-2)

• A2PE (bisretinoid precursor/adduct) and A2E (major bisretinoid/lipofuscin fluorophore): A2PE forms in OS and is hydrolyzed to A2E in RPE phagolysosomes; A2E accumulates as lipofuscin and is linked to RPE dysfunction and oxidative stress. (wang2023updatesonemerging pages 2-4, watson2023unravellingstargardtdisease pages 35-39, fujinami2024stargardtmaculardystrophy pages 2-2)

3.3 Cell types (CL terms; main affected compartments)

• Retinal pigment epithelial cell (RPE): central site of lipofuscin accumulation, phagocytosis of photoreceptor OS tips, and lysosomal pathology (elevated lysosomal pH, CatD impairment). (ng2024impairedcathepsind pages 1-3)

• Photoreceptor cells (rods and cones): ABCA4 expression in outer segments; OS disc retinoid-adduct handling; secondary degeneration following RPE dysfunction; macular cone loss drives central vision loss. (wang2023updatesonemerging pages 2-4, ghenciu2024emergingtherapeuticapproaches pages 4-5)

• Müller glial cells: gliosis is proposed to underlie OCT external limiting membrane (ELM) thickening, an early biomarker in some cases. (watson2023unravellingstargardtdisease pages 35-39)

3.4 Anatomical locations (UBERON terms; tissue-level pathology)

• Retina (particularly macula/central retina): STGD1 causes progressive central macular involvement with outer retinal loss on OCT and characteristic FAF changes reflecting lipofuscin and atrophy. (wang2023updatesonemerging pages 2-4, gomezbenlloch2024opticalcoherencetomography pages 2-4)

• RPE–choroid interface: RPE is a monolayer between neurosensory retina and choroid; RPE atrophy/degeneration is quantified by FAF and OCT; some imaging shows “dark choroid” in a substantial fraction of patients. (ghenciu2024emergingtherapeuticapproaches pages 2-4, wang2023updatesonemerging pages 2-4)

  1. Biological processes and cellular components (GO-oriented pathophysiology mapping)

Below are knowledge-base–ready process/component mappings supported by the mechanistic literature above (GO terms are suggested labels; evidence citations refer to the biological phenomenon).

Disrupted biological processes (example GO term labels)

• Retinoid metabolic process / visual cycle (retinoid cycle): ABCA4 dysfunction disrupts clearance/processing of retinal–PE adducts and increases bisretinoid formation. (fujinami2024stargardtmaculardystrophy pages 2-2, wang2023updatesonemerging pages 2-4)

• Phagocytosis and photoreceptor outer segment processing (including LC3-associated phagocytosis, LAP): STGD1 RPE shows impaired OS degradation and altered PE distribution proposed to compromise LAP-related processing. (ng2024impairedcathepsind pages 1-3, ng2024impairedcathepsind pages 12-13)

• Lysosome organization and acidification (endo-lysosomal homeostasis): elevated lysosomal pH is observed in STGD1 RPE models and impairs CatD maturation/activity. (ng2024impairedcathepsind pages 1-3)

• Oxidative stress response / reactive oxygen species metabolic process: bisretinoid/lipofuscin described as generating ROS upon light exposure and promoting RPE apoptosis. (ghenciu2024emergingtherapeuticapproaches pages 4-5)

• Complement activation / regulation of complement cascade (context-dependent): complement-related components (CD59/C3/C5) are implicated in ABCA4-related inflammatory pathways and RORA-modifier effects, though some assays find no clear C3 changes. (akula2024retinoicacidrelated pages 7-8, xie2024assayingtherole pages 36-40)

Cellular components (example GO CC labels)

• Photoreceptor outer segment disc membrane: localization of ABCA4 and site of N-ret-PE handling and bisretinoid precursor formation. (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 2-2)

• Lysosome / endo-lysosomal system (RPE): site of A2E/lipofuscin accumulation, lysosomal alkalinization, and CatD dysfunction; location where phagocytosed OS tips are degraded. (ng2024impairedcathepsind pages 1-3)

• Phagolysosome (RPE): acidic compartment where A2PE is hydrolyzed to A2E. (watson2023unravellingstargardtdisease pages 35-39)

  1. Disease progression: sequence of events and staging biomarkers

5.1 Sequence from molecular trigger to clinical manifestation

A synthesis consistent across recent sources:

1) ABCA4 functional impairment in photoreceptor OS disc membranes → accumulation of N-ret-PE / NrPE and increased formation of A2PE in OS membranes. (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 2-2)

2) OS shedding and RPE phagocytosis → hydrolysis of A2PE to A2E within acidic phagolysosomes → progressive RPE lipofuscin accumulation. (wang2023updatesonemerging pages 2-4, watson2023unravellingstargardtdisease pages 35-39)

3) RPE cellular stress (oxidative stress/photosensitization) and degradative impairment (elevated lysosomal pH; impaired CatD; impaired OS degradation; abnormal substrate accumulation such as α-synuclein) → RPE dysfunction and cell death. (ghenciu2024emergingtherapeuticapproaches pages 4-5, ng2024impairedcathepsind pages 1-3, ng2024impairedcathepsind pages 12-13)

4) Loss of RPE support (metabolic and trophic) → secondary photoreceptor dysfunction and death; in some eyes photoreceptor loss may precede overt RPE loss. (fujinami2024stargardtmaculardystrophy pages 2-2)

5.2 Imaging and functional biomarkers; genotype-phenotype considerations

Fundus autofluorescence (FAF)

• FAF detects lipofuscin-related autofluorescence and is widely prioritized as a trial endpoint; hyper-/hypoautofluorescent flecks and areas of decreased autofluorescence relate to atrophy and photoreceptor/RPE loss. (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 4-5)

Quantitative natural-history data (ProgStar)

• In a retrospective ProgStar subset (224 eyes; mean age 33.0±15.1 years), mean baseline “definitely decreased autofluorescence (DDAF)” area was 2.6 mm² and mean progression was 0.51 mm²/year. (fujinami2024stargardtmaculardystrophy pages 4-5)

OCT (SD-OCT)

• OCT can detect early external limiting membrane (ELM) thickening before visible fundus/FAF changes; ELM thickening is attributed to Müller cell gliosis in a disease-modeling synthesis. (gomezbenlloch2024opticalcoherencetomography pages 2-4, watson2023unravellingstargardtdisease pages 35-39)

• OCT-based definitions of complete RPE and outer retina atrophy (cRORA) criteria are summarized in a 2024 OCT review, supporting standardized atrophy detection and longitudinal measurement. (gomezbenlloch2024opticalcoherencetomography pages 2-4)

ERG groupings (prognosis)

• Prognostic grouping based on electrophysiology is described in 2023 and 2024 syntheses: Group 1 (macular dysfunction with normal ffERG) has best prognosis; Group 3 (cone+rod generalized dysfunction) has the worst prognosis; one review states all Group 3 patients show clinically significant worsening while ~20% of Group 1 show clinically significant progression. (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 4-5)

Epidemiologic/clinical early-stage observations

• In a pediatric cohort (280 children), 11.1% initially lacked fundus abnormalities, with a median diagnostic delay of 3 years; this supports the concept that early disease can be subtle and imaging/genetics are critical. (wang2023updatesonemerging pages 2-4)

  1. Phenotypic manifestations (HP-oriented summary)

Major phenotypes reported in recent clinical reviews include progressive central visual impairment, macular atrophy, fundus flecks (pisciform), delayed dark adaptation, and characteristic FAF/OCT changes (bull’s-eye patterns; peripapillary sparing; outer retinal loss). (wang2023updatesonemerging pages 2-4, gomezbenlloch2024opticalcoherencetomography pages 2-4)

  1. Recent developments (2023–2024) and expert synthesis

7.1 Mechanistic advances

• RPE-autonomous mechanism and lysosomal protease deficit: identification of CatD impairment and lysosomal alkalinization in patient iPSC-RPE models provides mechanistic leverage beyond the classical “lipofuscin toxicity” narrative and suggests lysosomal re-acidification as a therapeutic strategy. (ng2024impairedcathepsind pages 1-3, ng2024impairedcathepsind pages 12-13)

• Modifier/inflammation axis: RORA modifier gene therapy is presented as a translational strategy in Abca4−/− mice to modulate complement/inflammation-associated pathways (ABCA4, CD59, C3, C5) and improve functional readouts. (akula2024retinoicacidrelated pages 7-8)

7.2 Translational and clinical research landscape (selected real-world implementations)

Clinical trial registry examples (ClinicalTrials.gov)

• Metformin (macroautophagy rationale): “Oral Metformin for Treatment of ABCA4 Retinopathy” includes a qualifying-eye inclusion criterion requiring a square-root area ellipsoid-zone-loss growth rate >0.025 mm/year based on pre-existing natural-history data, highlighting the use of quantitative progression biomarkers for enrollment. (NCT04545736) (NCT04545736 chunk 2)

Therapeutic categories and notable study results (2023–2024 reviews)

• Lentiviral ABCA4 gene augmentation (EIAV; SAR422459; NCT01367444): 3-year follow-up of 22 patients is summarized; while no clinically significant visual-function changes attributable to treatment were reported, 6/22 (27%) showed worsening RPE atrophy on FAF. (wang2023updatesonemerging pages 6-7)

• AAV gene therapy development constraints: AAV’s ~4.7 kb packaging limit is repeatedly highlighted as a key barrier for full-length ABCA4 (6.8 kb), prompting dual-AAV and trans-splicing approaches (preclinical and early programs). (wang2023updatesonemerging pages 4-5)

• Stem cell / RPE replacement: hESC-derived RPE implantation trials are summarized, including reported safety (no adverse proliferation/rejection) and clinical observations (e.g., 13/18 (72%) with increasing subretinal pigmentation patches; BCVA improved in 10 eyes in one study summary). (fujinami2024stargardtmaculardystrophy pages 6-7)

• Autologous bone marrow-derived cell approaches (reported series): one review summarizes that 21/34 eyes (61.8%) improved, 8/34 (23.5%) were stable, and 5/34 (14.7%) progressed, with 94.1% improved or stable. (fujinami2024stargardtmaculardystrophy pages 7-7)

• Visual-cycle modulation: a 2024 review notes emixustat Phase 3 results showed “No meaningful differences between treatment groups regarding macular atrophy,” emphasizing mixed outcomes for visual-cycle suppression strategies. (fujinami2024stargardtmaculardystrophy pages 6-6)

• Complement inhibition: a 2024 therapeutic review lists intravitreal complement C5 inhibition (avacincaptad pegol/Zimura) as an active Phase 2 approach in STGD1 (NCT03364153). (fujinami2024stargardtmaculardystrophy pages 6-6)

  1. Evidence items (PMIDs and publication metadata where available)

PMID availability limitation: The provided full-text excerpts for 2023–2024 sources did not consistently include PubMed identifiers; thus, DOIs/URLs and publication months/years are used as primary identifiers for these recent works.

Key recent sources used for mechanistic/pathophysiology claims

• Ng ESY, Hu J, Jiang Z, Radu RA. “Impaired cathepsin D in retinal pigment epithelium cells mediates Stargardt disease pathogenesis.” The FASEB Journal. Published online June 15, 2024. https://doi.org/10.1096/fj.202400210RR (ng2024impairedcathepsind pages 1-3, ng2024impairedcathepsind pages 12-13)

• Fujinami K, Waheed N, et al. “Stargardt macular dystrophy and therapeutic approaches.” British Journal of Ophthalmology. 2024 (online; issue lists Nov 2024). https://doi.org/10.1136/bjo-2022-323071 (fujinami2024stargardtmaculardystrophy pages 4-5, fujinami2024stargardtmaculardystrophy pages 2-2)

• Wang L, Shah SM, Mangwani-Mordani S, Gregori NZ. “Updates on Emerging Interventions for Autosomal Recessive ABCA4-Associated Stargardt Disease.” Journal of Clinical Medicine. Sep 2023. https://doi.org/10.3390/jcm12196229 (wang2023updatesonemerging pages 2-4, wang2023updatesonemerging pages 6-7)

• Ghenciu LA, Hațegan OA, et al. “Emerging Therapeutic Approaches and Genetic Insights in Stargardt Disease: A Comprehensive Review.” International Journal of Molecular Sciences. Aug 2024. https://doi.org/10.3390/ijms25168859 (ghenciu2024emergingtherapeuticapproaches pages 2-4, ghenciu2024emergingtherapeuticapproaches pages 4-5)

• Akula M, McNamee SM, et al. “Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD.” Gene Therapy. May 2024. https://doi.org/10.1038/s41434-024-00455-z (akula2024retinoicacidrelated pages 7-8)

• Gómez-Benlloch A, Garrell-Salat X, et al. “Optical Coherence Tomography in Inherited Macular Dystrophies: A Review.” Diagnostics. Apr 2024. https://doi.org/10.3390/diagnostics14090878 (gomezbenlloch2024opticalcoherencetomography pages 2-4)

Appendix A. Knowledge-base style annotations (evidence-backed)

Disease identifiers

• Disease: Stargardt disease type 1 (STGD1) • OMIM: 248200 (wang2023updatesonemerging pages 1-2, ghenciu2024emergingtherapeuticapproaches pages 2-4)

Gene/protein annotations (HGNC symbol → evidence → suggested GO/process)

• ABCA4 → retinoid-adduct flippase in photoreceptor discs; loss leads to A2PE/A2E accumulation (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 2-2) – Suggested processes: retinoid metabolic process; transmembrane transport; photoreceptor outer segment disc membrane component

• CTSD (Cathepsin D) → primary RPE lysosomal protease; maturation/activity impaired with elevated lysosomal pH in STGD1 RPE models (ng2024impairedcathepsind pages 1-3) – Suggested processes: lysosomal proteolysis; phagocytosed outer-segment degradation

• SNCA (α-synuclein) → accumulates in STGD1 RPE with CatD dysfunction (ng2024impairedcathepsind pages 12-13) – Suggested processes: vesicle trafficking regulation; lysosome-related catabolism (contextual)

Phenotype associations (HP term labels; representative)

• Progressive central vision loss / macular atrophy / retinal flecks; delayed dark adaptation; FAF hyper/hypoautofluorescence patterns; OCT outer retinal loss (wang2023updatesonemerging pages 2-4, gomezbenlloch2024opticalcoherencetomography pages 2-4)

Cell types (CL) and anatomy (UBERON)

• RPE cell: lysosomal pH/CatD dysfunction; lipofuscin accumulation; OS phagocytosis defect (ng2024impairedcathepsind pages 1-3) • Photoreceptor (rod/cone) cells: ABCA4 in OS discs; bisretinoid precursor formation; secondary degeneration (wang2023updatesonemerging pages 2-4) • Müller glia: OCT ELM thickening attributed to gliosis (watson2023unravellingstargardtdisease pages 35-39) • Retina/macula: primary clinical locus of degeneration (gomezbenlloch2024opticalcoherencetomography pages 2-4)

Chemical entities (CHEBI names; representative)

• all-trans-retinal; phosphatidylethanolamine; A2PE; A2E; lipofuscin (wang2023updatesonemerging pages 2-4, fujinami2024stargardtmaculardystrophy pages 2-2)

Appendix B. Quantitative statistics extracted from recent sources

• Prevalence estimates: 1:8,000–1:10,000 (gomezbenlloch2024opticalcoherencetomography pages 2-4, wang2023updatesonemerging pages 1-2) • US prevalence estimate (reviewed): 10–12.5 per 100,000 (ghenciu2024emergingtherapeuticapproaches pages 2-4) • UK yearly incidence (reviewed): 0.11–0.12 per 100,000; Netherlands incidence 1.67–1.95 per 1,000,000 annually (ghenciu2024emergingtherapeuticapproaches pages 2-4) • Natural history (ProgStar, DDAF): baseline 2.6 mm²; progression 0.51 mm²/year (224 eyes) (fujinami2024stargardtmaculardystrophy pages 4-5) • Lentiviral ABCA4 gene therapy (SAR422459): 6/22 (27%) worsening RPE atrophy on FAF in 3-year follow-up summary (wang2023updatesonemerging pages 6-7) • Autologous bone marrow-derived cell series summary: 21/34 eyes improved (61.8%), 8/34 stable (23.5%), 5/34 progressed (14.7%) (fujinami2024stargardtmaculardystrophy pages 7-7)

End of report.

References

  1. (gomezbenlloch2024opticalcoherencetomography pages 2-4): Alba Gómez-Benlloch, Xavier Garrell-Salat, Estefanía Cobos, Elena López, Anna Esteve-Garcia, Sergi Ruiz, Meritxell Vázquez, Laura Sararols, and Marc Biarnés. Optical coherence tomography in inherited macular dystrophies: a review. Diagnostics, 14:878, Apr 2024. URL: https://doi.org/10.3390/diagnostics14090878, doi:10.3390/diagnostics14090878. This article has 10 citations.

  2. (wang2023updatesonemerging pages 1-2): Liang Wang, Serena M. Shah, Simran Mangwani-Mordani, and Ninel Z. Gregori. Updates on emerging interventions for autosomal recessive abca4-associated stargardt disease. Journal of Clinical Medicine, 12:6229, Sep 2023. URL: https://doi.org/10.3390/jcm12196229, doi:10.3390/jcm12196229. This article has 26 citations.

  3. (ng2024impairedcathepsind pages 1-3): Eunice Sze Yin Ng, Jane Hu, Zhichun Jiang, and Roxana A. Radu. Impaired cathepsin d in retinal pigment epithelium cells mediates stargardt disease pathogenesis. The FASEB Journal, Jun 2024. URL: https://doi.org/10.1096/fj.202400210rr, doi:10.1096/fj.202400210rr. This article has 8 citations.

  4. (fujinami2024stargardtmaculardystrophy pages 2-2): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.

  5. (wang2023updatesonemerging pages 2-4): Liang Wang, Serena M. Shah, Simran Mangwani-Mordani, and Ninel Z. Gregori. Updates on emerging interventions for autosomal recessive abca4-associated stargardt disease. Journal of Clinical Medicine, 12:6229, Sep 2023. URL: https://doi.org/10.3390/jcm12196229, doi:10.3390/jcm12196229. This article has 26 citations.

  6. (fujinami2024stargardtmaculardystrophy media 07d7554f): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.

  7. (fujinami2024stargardtmaculardystrophy media 5aab47f1): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.

  8. (watson2023unravellingstargardtdisease pages 35-39): AM Watson. Unravelling stargardt disease (stgd1): modelling genotype-phenotype correlations and unresolved genetic variants in ipsc-derived retinal organoids. Unknown journal, 2023.

  9. (ghenciu2024emergingtherapeuticapproaches pages 4-5): Laura Andreea Ghenciu, Ovidiu Alin Hațegan, Emil Robert Stoicescu, Roxana Iacob, and Alina Maria Șișu. Emerging therapeutic approaches and genetic insights in stargardt disease: a comprehensive review. International Journal of Molecular Sciences, 25:8859, Aug 2024. URL: https://doi.org/10.3390/ijms25168859, doi:10.3390/ijms25168859. This article has 23 citations.

  10. (ng2024impairedcathepsind pages 12-13): Eunice Sze Yin Ng, Jane Hu, Zhichun Jiang, and Roxana A. Radu. Impaired cathepsin d in retinal pigment epithelium cells mediates stargardt disease pathogenesis. The FASEB Journal, Jun 2024. URL: https://doi.org/10.1096/fj.202400210rr, doi:10.1096/fj.202400210rr. This article has 8 citations.

  11. (akula2024retinoicacidrelated pages 7-8): M. Akula, S. M. McNamee, Z. Love, N. Nasraty, ✉. N.P.M.Chan, M. Whalen, M. O. Avola, A. M. Olivares, B. D. Leehy, A. S. Jelcick, P. Singh, A. Upadhyay, D. F. Chen, N. Haider, and Gene Therapy. Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of stargardt disease and dry amd. Gene Therapy, 31:413-421, May 2024. URL: https://doi.org/10.1038/s41434-024-00455-z, doi:10.1038/s41434-024-00455-z. This article has 13 citations and is from a peer-reviewed journal.

  12. (xie2024assayingtherole pages 36-40): X Xie. Assaying the role of complement factor d on retinal pigment epithelial cell pathology in a mouse model of stargardt disease. Unknown journal, 2024.

  13. (xie2024assayingtherole pages 5-11): X Xie. Assaying the role of complement factor d on retinal pigment epithelial cell pathology in a mouse model of stargardt disease. Unknown journal, 2024.

  14. (yu2025mechanismsandfunctions pages 10-11): Xinyue Yu, Haobo Fan, Hui Zhang, and Xiaorong Li. Mechanisms and functions of chromophore regeneration in the classical visual cycle: implications for retinal disease pathogenesis and therapy. Biomolecules, 15:1676, Dec 2025. URL: https://doi.org/10.3390/biom15121676, doi:10.3390/biom15121676. This article has 0 citations.

  15. (ghenciu2024emergingtherapeuticapproaches pages 2-4): Laura Andreea Ghenciu, Ovidiu Alin Hațegan, Emil Robert Stoicescu, Roxana Iacob, and Alina Maria Șișu. Emerging therapeutic approaches and genetic insights in stargardt disease: a comprehensive review. International Journal of Molecular Sciences, 25:8859, Aug 2024. URL: https://doi.org/10.3390/ijms25168859, doi:10.3390/ijms25168859. This article has 23 citations.

  16. (fujinami2024stargardtmaculardystrophy pages 4-5): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.

  17. (NCT04545736 chunk 2): Oral Metformin for Treatment of ABCA4 Retinopathy. National Eye Institute (NEI). 2020. ClinicalTrials.gov Identifier: NCT04545736

  18. (wang2023updatesonemerging pages 6-7): Liang Wang, Serena M. Shah, Simran Mangwani-Mordani, and Ninel Z. Gregori. Updates on emerging interventions for autosomal recessive abca4-associated stargardt disease. Journal of Clinical Medicine, 12:6229, Sep 2023. URL: https://doi.org/10.3390/jcm12196229, doi:10.3390/jcm12196229. This article has 26 citations.

  19. (wang2023updatesonemerging pages 4-5): Liang Wang, Serena M. Shah, Simran Mangwani-Mordani, and Ninel Z. Gregori. Updates on emerging interventions for autosomal recessive abca4-associated stargardt disease. Journal of Clinical Medicine, 12:6229, Sep 2023. URL: https://doi.org/10.3390/jcm12196229, doi:10.3390/jcm12196229. This article has 26 citations.

  20. (fujinami2024stargardtmaculardystrophy pages 6-7): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.

  21. (fujinami2024stargardtmaculardystrophy pages 7-7): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.

  22. (fujinami2024stargardtmaculardystrophy pages 6-6): Kaoru Fujinami, Nadia Waheed, Yannik Laich, Paul Yang, Yu Fujinami-Yokokawa, Joseph J Higgins, Jonathan T Lu, Darin Curtiss, Cathryn Clary, and Michel Michaelides. Stargardt macular dystrophy and therapeutic approaches. The British Journal of Ophthalmology, 108:495-505, Nov 2024. URL: https://doi.org/10.1136/bjo-2022-323071, doi:10.1136/bjo-2022-323071. This article has 31 citations.